# name
Extracellular Vesicles Derived from Plasmodium-infected and
Non-infected Red Blood Cells as Targeted Drug Delivery Vehicles

# metadata.dc.description.abstract[].value
Among several factors behind drug resistance evolution in
malaria is the challenge of administering overall doses that are not toxic for the patient but that, locally, are sufficiently
high to rapidly kill the parasites. Thus, a crucial antimalarial
                strategy is the development of drug delivery systems capable of
                targeting antimalarial compounds to Plasmodium with high
                specificity. In the present study, extracellular vesicles (EVs)
                have been evaluated as a drug delivery system for the treatment
                of malaria. EVs derived from naive red blood cells (RBCs) and
                from Plasmodium falciparum-infected RBCs (pRBCs) were isolated
                by ultrafiltration followed by size exclusion chromatography.
                Lipidomic characterization showed that there were no significant
                qualitative differences between the lipidomic profiles of
                pRBC-derived EVs (pRBC-EVs) and RBC-derived EVs (RBC-EVs). Both
                EVs were taken up by RBCs and pRBCs, although pRBC-EVs were more
                efficiently internalized than RBC-EVs, which suggested their
                potential use as drug delivery vehicles for these cells. When
                loaded into pRBC-EVs, the antimalarial drugs atovaquone and
                tafenoquine inhibited in vitro P. falciparum growth more
                efficiently than their free drug counterparts, indicating that
                pRBC-EVs can potentially increase the efficacy of several small
                hydrophobic drugs used for the treatment of malaria.

# metadata.dc.relation.ispartof[].value
International Journal of Pharmaceutics, 2020, vol 587, num.119627

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Extracellular Vesicles Derived from Plasmodium-infected and
Non-infected Red Blood Cells as Targeted Drug Delivery Vehicles